Bilateral panuveitis following intravesical BCG immunotherapy for bladder carcinoma.
OBJECTIVE
To report a case of bilateral panuveitis following local treatment with Bacille Calmette-Guérin (BCG) immunotherapy for superficial bladder carcinoma.


METHODS
Case report and literature review.


METHODS
A 70-year-old female presented with severe bilateral anterior chamber inflammation 5 days after intravesical BCG instillation. Despite topical steroids and mydriatics, inflammation worsened and bilateral optic nerve swelling developed.


RESULTS
Oral corticosteroids settled the ocular inflammation, and optic nerve function recovered. A trial of steroid cessation caused rebound uveitis, so she remains on maintenance doses of oral corticosteroid.


CONCLUSIONS
Ocular inflammations following BCG therapy for bladder cancer are rare, and little is known about the management of such cases. This is the first report of bilateral panuveitis with optic nerve edema following such treatment.
Uppal
Gurmit S
GS
Moorfields Eye Hospital, London, UK.
Shah
Anish N
AN
Tossounis
Charalambos M
CM
Tappin
Michael J
MJ
D000283:Administration, Intravesical; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001500:BCG Vaccine / Q000009:adverse effects* / Q000627:therapeutic use; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy*; D003907:Dexamethasone / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects*; D009184:Mydriatics / Q000627:therapeutic use; D015864:Panuveitis / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology*; D011239:Prednisolone / Q000627:therapeutic use; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*; D014792:Visual Acuity / Q000187:drug effects
D000893:Anti-Inflammatory Agents; D001500:BCG Vaccine; D009184:Mydriatics; D003907:Dexamethasone; D011239:Prednisolone